Compare BTU & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | IMNM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2001 | 2020 |
| Metric | BTU | IMNM |
|---|---|---|
| Price | $25.18 | $19.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $31.58 | ★ $35.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,861,500,000.00 | $6,941,000.00 |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $9.42 | $18,747.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.06 | $13.53 |
| 52 Week High | $41.14 | $30.06 |
| Indicator | BTU | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 30.12 |
| Support Level | $23.51 | $19.39 |
| Resistance Level | $30.41 | $23.48 |
| Average True Range (ATR) | 1.02 | 1.12 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 42.71 | 13.81 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.